REFERENCES
1. Piñero F, Poniachik J, Ridruejo E, Silva M. Hepatocellular carcinoma in Latin America: diagnosis and treatment challenges. World J Gastroenterol 2018;24:4224-9.
2. Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, et al. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol 2010;9:63-9.
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mather C, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. In J Cancer 2015;136:E359-86.
4. Mcglynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223-38.
5. Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, et al. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13:S4-40.
6. Piñero F, Pages J, Marciano S, Fernández N, Silva J, et al. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018;10:41-50.
7. IARC/WHO. GLOBOCAN 2019: Estimated cancer incidence, mortality and prevalence worldwide in 2019. Cancer today data base, Population Fact Sheets. Available from: https://gco.iarc.fr/today/fact-sheets-populations [Last accessed on 16 Apr 2020].
8. Piñeiro F, Costa P, Boteon YL, Duque SH, Marciano S, et al. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clin Res Hepatol Gastroenterol 2018;42:443-52.
9. World Health Organization. Hepatitis B and C in the spotlight, a public health response in the America. 2016. Available from: http://iris.paho.org/xmlui/bitstream/handle/123456789/31449/9789275119297eng.pdf?sequence=5&isAllowed=y [Last accessed on 16 Apr 2020].
10. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76.
11. World Health Organization. Global Hepatitis Report, World Health Organization. 2017. Available from: http://www.who.int/hepatitis [Last accessed on 16 Apr 2020].
12. Centers for Disease Control and Prevention. The ABCs of Hepatitis Fact Sheet. 2016. Available from: www.cdc.gov/hepatitis [Last accessed on 16 Apr 2020].
13. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 2019;70:674-83.
14. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-35.
15. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011;31:18-29.
16. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer 2018;142:2471-7.
17. Motola-Kuba D, Zamora-Valdes D, Uribe M, Méndez-Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006;5:16-24.
18. González Huezo MS, Sánchez Ávila JF, et al; Asociación Mexicana de Hepatología; Asociación Mexicana de Gastroenterología; Sociedad Mexicana de Radiología e Imagen. Mexican consensus on the diagnosis and management of hepatocellular carcinoma. Rev Gastroenterol Mex 2014;79:250-62.
19. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004;3:30-3.
20. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50.
21. Weissenbacher M, Rossi D, Radulich G, Sosa-Estáni S, Vila M, et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis 2003;15:S348-52.
22. Guimarães T, Granato CF, Varella D, Ferraz ML, Castelo A, et al. High prevalence of hepatitis C infection in a Brazilian prisión: identification of risk factors for infection. Braz J Infect Dis 2001;5:111-28.
23. Pando MA, Bautista CT, Maulen S, Duranti R, Marone R, et al. Epidemiology of human immunodeficiency virus, viral hepatitis (B and C), treponema pallidum, and human T-cell, and human T-cell lymphotropic I/II virus among men who have sex with men in Buenos Aires Argentina. Sex Transm Dis 2006;33:307-13.
24. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, et al. The effect of PNPLA3 on fibrosis progression and development of the hepatocellular carcinoma a meta-analysis. Am J Gastroenterol 2014;109:325-24.
25. Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic fatty liver disease in Latinos. Clin Gastroenterol Hepatol 2016;14:5-12.
26. Nordenstedt H, White D, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42:s206-14.
27. Jiwani SS, Carrillo Larco RM, Hernández-Vásquez A, Barrientos-Gutiérrez T, Basto-Abreu A, et al. The shift of obesity burden by socioeconomic status between 1998 and 2017 in Latin America and the Caribbean: a cross-sectional series study. Lancet Glob Health 2019;7:e1644-54.
28. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017;390:2627-42.
29. Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdés P, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005;4:52-5.
30. Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am 2002;31:641-62.
31. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-protein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-28.
32. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. GUT 2011;60:992-7.
33. Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
34. European Association for the study of the liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
35. Heimbach J, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.
36. Marrero JA, Ahn J, Rajender Reddy K; American College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 2014;109:1328-47.
37. Kudo M, Matsui O, Izumi N, lijima H, Kadoya M, et al. JSH-consensus-based clinical practice guideline for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 2014;3:458-68.
38. Matsui O. Analysis of intranodular hemodynamics of dysplastic nodules in cirrhotic livers. Radiology 2001;218:603-5.
39. Ueda K, Tereda T, Nakanuma Y, Matsui O. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study. Hum Pathol 1992;23:619-26.
40. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnosis criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
41. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, et al. The diagnosis and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-44.
42. Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WR, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42:27-34.
43. Hanna RF, Milousshev VZ, Tang A, Finklestone LA, Brejt SZ, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol 2016;41:71-90.
44. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, et al. Hepatocellular carcinoma: diagnosis performance of multidetector CT and MR imaging a system review and meta-analysis. Radiology 2015;275:97-109.
45. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018;67:401-21.
46. Kierans AS, Kang SK, Rosenkrantz AB. The diagnosis performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology 2016;278:82-94.
47. Kele PG, Van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol 2010;16:1567-76.
48. Miller FH, Hammond N, Siddiqi AJ, Shroff S, Khatri G, et al. Utility of difussion-weighted MRI in distinguishing benign and malignant hepatic lesion. J Magn Reson Imaging 2010;32:138-47.
49. Galea N, Cantisani V, Taouli B. Liver lesion detection and characterization: role of diffusion-weighted imaging. J Magn Reson Imaging 2013;37:1260-76.
50. Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012;57:421-9.
51. Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004;53:1356-62.
52. International Consensus Group for Hepatocellular Neoplasia, The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
53. Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol 2019;11:1758835919848184.
54. Kawai T, Akira S. The roles of TLRs, RLSs and NLRs in pathogen recognition. Int Immunol 2009;21:317-37.
55. Miao EA, Andersen-Nissen E, Warren SE, Aderem A. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol 2007;29:275-88.
56. Luedde T, Schwabe RF. NF-kB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108-28.
57. Jung IH, Choi JH, Chung YY, Lim GL, Park YN, et al. Predominant acivation of JAK/STAT3 pathway by interleukin-6 is implicated in hepatocarcinogenesis. Neoplasia 2015;17:586-697.
58. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updatecrietria and genotype assignment web resource. Hepatology 2013;59:318-27.
59. Arca-Lafuente S, Martínez-Román P, Mateo-Cano I, Madrid R, Briz V. Nanotechnology: a reality for diagnosis of HCV infectious disease. J Infect 2019;30:30281-6.
60. Hussain MM, Samir TM, Azzazy HME. Unmodified gold nanoparticles for direct and rapid detection of mycobacterium tuberculosis complex. Clin Biochem 2013;46:633-7.
61. Gill P, Alvandi A, Abdul-tehrani H, Sadeghizadeh M. Colorimetric detection of helicobacter pylori DNA using isothermal helicase-dependent amplification and gold nanoparticle probes. Diagn Microbiol Infect Dis 2008;62:119-24.
62. Carter JR, Balaram V, Kucharski CA, Fraser TS, Fraser MJ. A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches. Virol J 2013;10:201.
63. Liu Y, Zhang L, Wei W, Zhao H, Zhou Z, et al. Colorimetric detection in influenza a virus using antibody-functionalized gold nanoparticles. Analyst 2015;140:3989-95.
64. Wang C, Zhang L, Shen X. Development of a nucleic acid lateral flow strip for detection of hepatitis C virus (HCV) core antigen. Nucleosides Nucleotides Nucl Acids 2013;32:59-68.
65. Daniele B, Bencivenga A, Megna AS, Tinessa V. a-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108-12.
66. Fassio E, Mazzolini G; AAEEH. Consenso y guías Argentinas para la vigilancia, Diagnóstico y Tratamiento del Hepatocarcinoma. Acta Gastroenterol Latinoam 2016;46:350-74. (in Spanish)
67. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
68. Meza-Junco J, Montaño-Loza A, Myrna C. Treatment modalities in patients with hepatocellular carcinoma: a restrospective series in a single institution in Mexico. Gastroenterol Hepatol 2004;27:11-7.
69. Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001;234:71-8.
70. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection marging in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 2000;23:544-51.
71. Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999;86:1032-38.
72. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005;242:252-9.
73. Kosuge T, Makuuchi M, Takayama T, Yamamoto J, Shimada K, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 1993;40:328-32.
74. Carrilho FJ, Kikuchi L, Branco F, Sandoval Goncalves C, Aves de Mattos A, et al. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics 2010;65:1285-90.
75. Fan ST. Hepatocellular carcinoma- resection or transplant? Nat Rev Gastroenterol Hepatol 2012;9:732-37.
76. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus coference report. Lacet Oncol 2012;13:e11-22.
77. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17:S44-57.
78. Sociedad de Trasplantes de América Latina y el Caribe (Stalyc). Newsletter transplant international figures on donation and transplantation 2016. Available from: https://stalyc.net/utilidades/biblioteca/publicaciones/file/94-newsletter-transplant-22.html [Last accessed on 16 Apr 2020].
79. Sociedad de Trasplantes de América Latina y el Caribe (Stalyc). Latin America Transplantation Registry Report 2015-2016. Available from: https://www.stalyc.net/registros/file/74-latin-america-transplantation-registry-report-2015-2016.html [Last accessed on 16 Apr 2020].
80. Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: current evidence and future directions. World J Gastroenterol 2019;28:4614-28.
81. N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009;50:1475-83.
82. Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005;234:954-60.
83. Sato S, Shiratori Y, Imamura M, Teratani T, Obi S, et al. Power Doopler signals after percutaneous ethanol injection therapy for hepatocellular carcinoma predict local recurrence of tumors: a prospective study using 199 consecutive patients. J Hepatol 2001;35:225-34.
84. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012;262:43-58.
85. Khan KN, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000;32:269-78.
87. Glassberg MB, Ghosh S, Clymer JW, Wright GWJ, Ferko N, et al. Microwave ablation compared with hepatic resection for the treatmemt of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. World J Surg Oncol 2019;17:98.
88. Doo Song K. Percutaneous cryoablation for hepatocellular carcinoma. Clin Mol Hepatol 2016;22:509-15.
89. Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma 2017;13:49-58.
90. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42.
91. Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, et al. Transarterial radioembolization (TARE) agents beyond 90Y microspheres. Biomed Res International 2018;2018:1-14.
92. Hsieh TC, Wu YC, Sun SS, Yen KY, Kao CH. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. Biomedicine 2016;6:19.
93. Bruix J, Sherman M; American Association for the Study of the Liver Diseases. Management of hepatocellular carcinoma: an up date. Hepatology 2011;53:1020-2.
94. Leathers JS, Balderramo D, Prieto J, Diehl F, Gonzalez-Ballerga E, et al. Sorafenib for treatment of hepatocellular carcinoma: a survival analysis from the south american liver research network. J Clin Gastroenterol 2019;53:464-9.
95. Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterol 2019;156:510-24.
96. De Mattia E, Cecchin E, Guardascione M, Foltran L, Raimo TD, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol 2019;25:3870-96.
97. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
98. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
99. Turkes F, Chau I. Ramucirumab and its use in the treatment of hepatocellular carcinoma. Future Oncol 2019;15:979-88.
100. Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2018;18:1169-75.
101. Wang J, Ma L, Tang X, Zhang X, Qiao Y, et al. Doxorubicin induces apoptosis by targeting Madcam 1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells. Oncotarget 2015;6:24075-91.
102. Zhou Y, Li K, Li F, Han S, Wang Y, et al. Doxorubicin and ABT-199 coencapsulated nanocarriers for targeted delivery and synergistic treatment against hepatocellular carcinoma. J Nanomat 2019;2019:13.
103. Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PloS One 2013;8:e61361.
104. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther 2012;135:44-53.
105. Nishiguchi S, Kuroti T, Nakatani S, Morimoto H, Takeda T, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
106. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnú L, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HVC-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
107. Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology 2019;156:431-45.
108. Piñero F, Boin I, Chagas A, Quiñonez E, Marciano S, et al. Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher waitlist progression or post-transplant recurrence. Liver Transpl 2020. epub ahead of print. doi: 10.1002/lt.25744
